Chemed (NYSE:CHE) CEO Sells 2,000 Shares of Company Stock

Chemed Corporation (NYSE:CHE) CEO Kevin Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $537.90, for a total value of $1,075,800.00. Following the completion of the transaction, the chief executive officer owned 82,220 shares in the company, valued at $44,226,138. This represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Chemed Price Performance

Shares of NYSE:CHE traded down $15.21 on Thursday, hitting $533.43. The company’s stock had a trading volume of 137,324 shares, compared to its average volume of 201,328. The company has a market capitalization of $6.95 billion, a PE ratio of 25.52, a PEG ratio of 2.03 and a beta of 0.50. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.11 and a quick ratio of 1.08. The company has a 50-day simple moving average of $514.63 and a 200 day simple moving average of $464.29. Chemed Corporation has a 1 year low of $365.20 and a 1 year high of $562.24.

Chemed (NYSE:CHE) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $6.75 EPS for the quarter, topping the consensus estimate of $6.44 by $0.31. The company had revenue of $690.94 million during the quarter, compared to analyst estimates of $685.04 million. Chemed had a return on equity of 35.18% and a net margin of 10.61%. Chemed’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.27 earnings per share. Sell-side analysts forecast that Chemed Corporation will post 24.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Illinois Municipal Retirement Fund grew its holdings in shares of Chemed by 23.4% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 14,971 shares of the company’s stock valued at $7,561,000 after purchasing an additional 2,842 shares during the last quarter. Lido Advisors LLC raised its position in Chemed by 88.3% in the 3rd quarter. Lido Advisors LLC now owns 966 shares of the company’s stock worth $488,000 after purchasing an additional 453 shares during the period. AlphaCore Capital LLC lifted its stake in Chemed by 6.4% in the third quarter. AlphaCore Capital LLC now owns 1,046 shares of the company’s stock worth $528,000 after purchasing an additional 63 shares during the last quarter. Fulcrum Asset Management LLP lifted its stake in Chemed by 121.9% in the third quarter. Fulcrum Asset Management LLP now owns 71 shares of the company’s stock worth $36,000 after purchasing an additional 39 shares during the last quarter. Finally, Ethic Inc. boosted its position in Chemed by 20.0% during the third quarter. Ethic Inc. now owns 1,343 shares of the company’s stock valued at $678,000 after buying an additional 224 shares during the period. 95.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on CHE shares. Wall Street Zen raised shares of Chemed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 10th. Oppenheimer raised their price objective on shares of Chemed from $590.00 to $625.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. Weiss Ratings raised shares of Chemed from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. UBS Group upped their target price on shares of Chemed from $650.00 to $675.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Finally, Bank of America reissued a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $603.00.

About Chemed

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.